| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
AChE-IN-3 has dual targets: acetylcholinesterase (AChE) and the pathway(s) leading to nitric oxide (NO) production (likely inducible nitric oxide synthase, iNOS, or related signaling). It shows moderate inhibition of AChE and a stronger inhibitory effect on NO production, with an EC50 of 0.57 uM for NO inhibition.
|
|---|---|
| ln Vitro |
In vitro, AChE-IN-3 shows moderate inhibitory activity against acetylcholinesterase (AChE) and strong inhibitory activity against nitric oxide (NO) production, with an EC50 of 0.57 uM for NO inhibition. The specific IC50 for AChE is not provided, but it is characterized as “moderate.” This dual activity is its defining feature.
|
| ln Vivo |
In vivo activity data for AChE-IN-3 is not detailed in these references. By inhibiting both AChE (which enhances cholinergic signaling) and NO production (which reduces nitrosative stress), the compound is hypothesized to have potential in models of Alzheimer's disease and other neuroinflammatory conditions, though specific in vivo efficacy data is not reported here.
|
| Enzyme Assay |
The non-cellular AChE inhibition assay is performed using a standard colorimetric method. Electric eel or rat brain AChE is incubated with varying concentrations of AChE-IN-3 in Tris-HCl buffer. The substrate acetylthiocholine and Ellman's reagent (DTNB) are added. After 30 minutes, the production of the yellow thionitrobenzoate anion is measured at 412 nm to calculate the residual enzyme activity and the IC50 for AChE inhibition.
|
| Cell Assay |
To measure the inhibition of NO production, RAW 264.7 murine macrophage cells are seeded in 96-well plates and treated with varying concentrations of AChE-IN-3 (e.g., 0.1-100 uM) in the presence of 1 ug/mL lipopolysaccharide (LPS) to induce iNOS expression. After 24 hours, the culture supernatant is collected, and the concentration of nitrite (NO2-), a stable end product of NO, is measured using the Griess reagent assay. The EC50 for NO inhibition is calculated.
|
| Animal Protocol |
No specific in vivo animal protocol for AChE-IN-3 is described. A typical protocol for testing a dual AChE/NO inhibitor would involve administering the compound orally or intraperitoneally to a rodent model of Alzheimer‘s disease (e.g., streptozotocin-induced or transgenic model). After a treatment period, cognitive function is assessed by the Morris water maze, and brain tissue is analyzed for AChE activity, NO levels, and inflammatory markers (e.g., IL-1beta, TNFalpha).
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for AChE-IN-3 is not provided. As a small molecule with a molecular weight of approximately 427.45 g/mol, it may be formulated for in vivo administration using vehicles such as 10% DMSO, 40% PEG300, 5% Tween 80, and 45% saline. Its solubility in DMSO is 90 mg/mL (210.55 mM), which facilitates preparation of stock solutions.
|
| Toxicity/Toxicokinetics |
Toxicity data for AChE-IN-3 is not detailed. As an AChE inhibitor, potential toxicities would be cholinergic in nature (e.g., GI distress, muscle fasciculations) at high doses, while the strong NO inhibition might affect cardiovascular function (e.g., blood pressure regulation). Specific LD50 or NOAEL values are not provided in the available references.
|
| References |
[1]. Ren B, et al. Imidazolylacetophenone oxime-based multifunctional neuroprotective agents: Discovery and structure-activity relationships. Eur J Med Chem. 2022 Jan 15;228:114031.
|
| Additional Infomation |
AChE-IN-3 represents a “multifunctional” drug design approach, which is highly relevant for treating complex diseases like Alzheimer's disease that involve multiple pathological mechanisms (cholinergic deficit, neuroinflammation, oxidative stress). By incorporating both AChE inhibition and NO inhibition into a single molecule, it offers a potential advantage over single-target drugs, and its synthesis was reported in the context of developing imidazolylacetophenone oxime-based multifunctional neuroprotective agents.
|
| Molecular Formula |
C25H21N3O4
|
|---|---|
| Molecular Weight |
427.451946020126
|
| Exact Mass |
427.153
|
| CAS # |
2713548-95-7
|
| PubChem CID |
162641690
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
711
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C=C(/C(/CN3C=NC=C3)=N\OC(C3=CC=C4C=CC=CC4=C3)=O)C=CC=2OC1(C)C
|
| InChi Key |
HAHPBHJWRHEGQZ-MEFGMAGPSA-N
|
| InChi Code |
InChI=1S/C25H21N3O4/c1-25(2)30-22-10-9-19(14-23(22)31-25)21(15-28-12-11-26-16-28)27-32-24(29)20-8-7-17-5-3-4-6-18(17)13-20/h3-14,16H,15H2,1-2H3/b27-21-
|
| Chemical Name |
[(E)-[1-(2,2-dimethyl-1,3-benzodioxol-5-yl)-2-imidazol-1-ylethylidene]amino] naphthalene-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (233.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.85 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3395 mL | 11.6973 mL | 23.3945 mL | |
| 5 mM | 0.4679 mL | 2.3395 mL | 4.6789 mL | |
| 10 mM | 0.2339 mL | 1.1697 mL | 2.3395 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
